Our pipeline
We are advancing a broad pipeline of potentially best-in-class biotherapeutics, with initial focus on immune-mediated disease. Learn more about the programs we are developing below.
Our pipeline
We are advancing a broad pipeline of potentially best-in-class biotherapeutics, with initial focus on immune-mediated disease. Learn more about the programs we are developing below.
Immunology
| PROGRAM | TARGET | DISCOVERY | IND ENABLING | Phase 1 |
|---|---|---|---|---|
 ATTO-1310 |
IL31 |
|
||
| Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque in dignissim dolor. Sed a ornare augue. Fusce tincidunt ut tellus et fermentum. | ||||
| ATTO-3712 |
IL31 X IL13 |
|
||
| ATTO-004 |
Undisclosed bi- or tri-specific |
|
||
| ATTO-005 |
Two immune cell targets |
|
||
Immunology
| PROGRAM | TARGET |
|---|---|
| ATTO-1310 |
IL31 |
|
|
|
| Phase 1 | |
| ATTO-3712 |
IL31 X IL13 |
|
|
|
| Â IND ENABLING | |
| ATTO-004 |
Undisclosed bi- or tri-specific |
|
|
|
| DISCOVERY | |
| ATTO-005 |
Two immune cell targets |
|
|
|
| DISCOVERY | |
ATTOBODIES: the binder of choice for multispecifics
ATTOBODIES are an attractive new modality for the development of bispecifics and multispecifics. We are open to collaborations exploring the potential of our ATTOBODIES to enrich and improve our partners’ development pipelines and discovery efforts.